These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22920643)

  • 1. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloma kidney: improving clinical outcomes?
    Haynes R; Leung N; Kyle R; Winearls CG
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):342-51. PubMed ID: 22920645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management options for cast nephropathy in multiple myeloma.
    Cockwell P; Hutchison CA
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    Sinisalo M; Silvennoinen R; Wirta O
    Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial.
    Bridoux F; Fermand JP
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):333-41. PubMed ID: 22920644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
    Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute kidney injury with cast nephropathy.
    Walther C; Podoll AS; Finkel KW
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
    Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
    Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of free light chain hemodialysis in myeloma cast nephropathy: a case-control study.
    Peters NO; Laurain E; Cridlig J; Hulin C; Cao-Huu T; Frimat L
    Hemodial Int; 2011 Oct; 15(4):538-45. PubMed ID: 22111823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improved prognosis in light chain nephropathy due to multiple myeloma].
    Juul JS; Larsen T; Marcussen N; Pedersen EB
    Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.
    Fabbrini P; Finkel K; Gallieni M; Capasso G; Cavo M; Santoro A; Pasquali S
    J Nephrol; 2016 Dec; 29(6):735-746. PubMed ID: 27757797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal treatment of cast nephropathy.
    Gakhar B; Kobrin S; Berns JS
    Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
    Ward F; Dunne O; Crotty TB; Fennelly D; Watson A; Holian J
    Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
    Hada R; Poudyal B; Sharma A; Khatri R
    JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cast nephropathy with acute renal failure treated with high cut-off haemodialysis in a patient with multiple myeloma.
    Shum HP; Chan KC; Chow CC; Kho BC; Yan WW
    Hong Kong Med J; 2010 Dec; 16(6):489-92. PubMed ID: 21135429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended high cutoff on-line hemodiafiltration is superior to extended high cutoff hemodialysis in removal of free light chain immunoglobulin of myeloma cast nephropathy.
    Susantitaphong P; Tiranathanagul K; Eiam-Ong S
    Artif Organs; 2012 Sep; 36(9):845-6. PubMed ID: 22497276
    [No Abstract]   [Full Text] [Related]  

  • 20. Renal improvement in myeloma with plasma exchange.
    Hutchison C; Bridoux F; Fermand JP
    N Engl J Med; 2011 Sep; 365(11):1061; author reply 1062. PubMed ID: 21916654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.